3.6971

1.51% 0.0571

Iovance Biotherapeutics Inc (IOVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché IOVA Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.64

Aprire:

$3.68

Volume 24 ore:

7.12M

Relative Volume:

0.46

Capitalizzazione di mercato:

$1.52B

Reddito:

$263.44M

Utile/perdita netta:

$-390.98M

Rapporto P/E:

-3.298

EPS:

-1.121

Flusso di cassa netto:

$-336.24M

1 W Prestazione:

+6.48%

1M Prestazione:

-6.69%

6M Prestazione:

+64.96%

1 anno Prestazione:

+14.40%

Intervallo 1D:

$3.53

$3.71

Intervallo di 1 settimana:

$3.42

$4.31

Portata 52W:

$1.6385

$5.63

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Nome

Iovance Biotherapeutics Inc

Settore

Healthcare (1114)

Industria

Biotechnology (622)

Telefono

(650) 260-7120

Indirizzo

825 INDUSTRIAL ROAD, SAN CARLOS

Dipendente

975

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IOVA Iovance Biotherapeutics Inc	3.695	1.50B	263.44M	-390.98M	-336.24M	-1.121
VRTX Vertex Pharmaceuticals Inc	442.76	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	748.47	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	842.22	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	335.30	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	317.07	34.41B	5.36B	287.73M	924.18M	2.5229

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-25	Aggiornamento	Citizens	Mkt Perform → Mkt Outperform
2025-07-15	Downgrade	Goldman	Neutral → Sell
2025-05-16	Downgrade	UBS	Buy → Neutral
2025-05-12	Downgrade	Truist	Buy → Hold
2025-05-09	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
2024-10-24	Iniziato	UBS	Buy
2024-07-29	Downgrade	Piper Sandler	Overweight → Neutral
2023-11-20	Iniziato	Goldman	Buy
2023-09-18	Reiterato	Barclays	Overweight
2023-05-30	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-27	Ripresa	Wells Fargo	Equal Weight
2023-01-27	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-12-09	Downgrade	Goldman	Buy → Neutral
2022-10-31	Iniziato	Guggenheim	Neutral
2022-08-18	Ripresa	Wells Fargo	Equal Weight
2022-01-28	Aggiornamento	Stifel	Hold → Buy
2021-12-07	Ripresa	Cowen	Outperform
2021-06-10	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Downgrade	Piper Sandler	Overweight → Neutral
2021-05-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Downgrade	Stifel	Buy → Hold
2021-05-03	Iniziato	Truist	Buy
2021-04-16	Iniziato	Goldman	Buy
2021-03-08	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-15	Downgrade	H.C. Wainwright	Buy → Neutral
2020-10-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-04-22	Iniziato	Mizuho	Buy
2020-03-04	Iniziato	Barclays	Overweight
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-02-26	Reiterato	Oppenheimer	Outperform
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-10-01	Iniziato	Stifel	Buy
2019-04-29	Iniziato	Piper Jaffray	Overweight
2019-02-28	Reiterato	Chardan Capital Markets	Buy
2019-02-07	Iniziato	Robert W. Baird	Outperform
2018-12-31	Ripresa	B. Riley FBR	Buy
2018-07-06	Reiterato	Chardan Capital Markets	Buy
2018-04-10	Aggiornamento	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Reiterato	B. Riley FBR, Inc.	Neutral
2018-02-23	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Reiterato	H.C. Wainwright	Buy
2017-11-01	Reiterato	B. Riley FBR, Inc.	Buy

Mostra tutto

Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie

Apr 13, 2026

REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN

Apr 13, 2026

Apr 11, 2026

IOVA Deadline: IOVA Investors Have Opportunity to Lead Iovance B - GuruFocus

Apr 11, 2026

Macro Review: Will Iovance Biotherapeutics Inc benefit from green energy policiesDividend Hike & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Apr 11, 2026

REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits

Apr 11, 2026

IOVA stock slump takes Wall Street, retail by surprise — here’s why - MSN

Apr 11, 2026

Iovance Biotherapeutics: Analyzing Growth Potential and Risks After Amtagvi Approval - IndexBox

Apr 11, 2026

Iovance Biotherapeutics (IOVA) Is Up 16.9% After Stronger Real-World Amtagvi Data Spurs Franchise Hopes - Sahm

Apr 11, 2026

IOVA Maintained by Chardan Capital -- Price Target Stays at $16 - GuruFocus

Apr 11, 2026

Apr 10, 2026

IOVA Stock Grinds Sideways As Traders Weigh Heavy Losses - timothysykes.com

Apr 10, 2026

Iovance Biotherapeutics Faces Stock Decline Amid Market Dynamics - Intellectia AI

Apr 10, 2026

Jefferies reiterates Iovance Biotherapeutics stock rating at buy By Investing.com - Investing.com Canada

Apr 10, 2026

Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $16 - Moomoo

Apr 10, 2026

IOVA: Analyst Comments on FDA Rejection Impact - GuruFocus

Apr 10, 2026

Iovance Biotherapeutics (IOVA) Maintains Strong Outlook Amid Reg - GuruFocus

Apr 10, 2026

Iovance Biotherapeutics Faces Market Waves Amid Losses and Strategic Moves - timothysykes.com

Apr 10, 2026

Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - Yahoo Finance

Apr 10, 2026

Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - The Motley Fool

Apr 10, 2026

IOVA Stock Holds Key Support As Biotech Traders Circle - StocksToTrade

Apr 10, 2026

IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill

Apr 10, 2026

Apr 09, 2026

Iovance’s Landmark FDA Approval Shakes Up Melanoma Treatment Market - StocksToTrade

Apr 09, 2026

A Look At Iovance Biotherapeutics (IOVA) Valuation After Strong Amtagvi Data And Growing Pipeline Momentum - Sahm

Apr 09, 2026

Apr 08, 2026

Analyst sentiment remains strong on Iovance Biotherapeutics (IOVA) amid US rollout of melanoma drug, Amtagvi - MSN

Apr 08, 2026

Aug Fed Impact: How correlated is Iovance Biotherapeutics Inc to the S P5002026 Top Gainers & Community Shared Stock Ideas - baoquankhu1.vn

Apr 08, 2026

Market Review: How correlated is Iovance Biotherapeutics Inc to the S P500Portfolio Performance Summary & Low Risk High Reward Ideas - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving AverageHere's What Happened - MarketBeat

Apr 07, 2026

Apr 06, 2026

Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA) - Seeking Alpha

Apr 06, 2026

Apr 04, 2026

IOVA SEC FilingsIovance Biotherp 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 04, 2026

Apr 03, 2026

Why Is Iovance Biotherapeutics, Inc. (IOVA) Stock Down Today? - Meyka

Apr 03, 2026

Iovance Biotherapeutics (IOVA) Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed? - Sahm

Apr 03, 2026

Apr 02, 2026